JPMorgan missed Q3 estimates on October 13 while Goldman beat on equities trading; Wells and Citi were mixed. Accounting teams should update credit-loss and fair-value inputs with the latest bank commentary.

Eye injuries can cause permanent damage and life-changing consequences. Solicitors who specialize in these claims help victims navigate the legal process for fair compensation.

Bitzero Holdings (AIBZ) has amended and refiled its annual and interim financial statements and MD&A following a review by the British Columbia Securities Commission, to change the accounting classification of warrants linked to its senior secured loan as at September 30, 2025.With assistance from an independent valuation specialist, the JGB First Warrants are now classified under IFRS as derivative financial liabilities measured at fair value through profit or loss, rather than within senior secured loans, because they may result in a variable number of common shares and do not meet the IAS 32 “fixed-for-fixed” condition. This non-cash reclassification moved US$7,716,025 from non-current liabilities to current liabilities, increasing current liabilities from US$13,566,493 to US$21,282,518 and reducing non-current liabilities from US$16,323,514 to US$8,607,489, with total liabilities unchanged at US$29,890,007.Total assets (US$42,740,718), total shareholders’ equity (US$12,850,711), net loss (US$(16,548,342)) and cash and cash equivalents, as well as cash flows for the periods presented, were not affected. Working capital deficiency as at September 30, 2025 increased from US$(6,350,676) to US$(14,066,701). The amended and restated filings for the year ended September 30, 2025 and the three and nine months ended June 30, 2026 replace the prior versions and are available on SEDAR+.

DDC Enterprise (DDC) reported first half 2026 revenue of US$20.2 million, up 29% year over year, with gross profit rising 17.5% to US$6.1 million and its core food business generating positive non-GAAP Adjusted EBITDA of US$1.2 million.GAAP net loss was US$38.4 million, compared with a profit in the prior-year period, largely due to a US$34.3 million non-cash unrealized fair value loss on digital assets. Gross margin declined to 30.4% from 33.4% as the company expanded into higher-volume channels. Working capital improved from negative US$12.2 million at December 31, 2025 to positive US$39.4 million at June 30, 2026, and net debt fell from US$60.6 million to US$10.2 million. Total shareholders’ equity attributable to DDC increased to US$180.8 million, from approximately US$71.2 million at year-end 2025. DDC held 2,899 Bitcoin as of the release date, up 145% from 1,181 at December 31, 2025. The board also authorized a share repurchase program of up to US$10 million or 20% of outstanding Class A shares over up to 18 months.

Maris Tech (MTEK) reported first half 2026 revenues of approximately $2.1 million, a 194% increase over the same period in 2025.Revenues for the six months ended June 30, 2026, were $2,077,545 versus $707,021 a year earlier. The company recorded a net loss of $2,816,584, including $650,958 from fluctuations and changes in the fair value of financial instruments, compared with net income of $2,388,294 in first half 2025. Cash and cash equivalents stood at $2,387,801 as of June 30, 2026, down from $2,769,901 a year earlier. Management describes Maris Tech as a defense-focused provider of video and AI system solutions and notes that AS9100 certification supports competition for larger defense and aerospace projects.

Five major US spot XRP products held XRP with a combined fair value $746.1 million below accounting cost at the end of June, but investors kept buying anyway. According to SEC filings, Bitwise, Canary Capital, Franklin Templeton, 21Shares, and Grayscale recorded roughly $629.9 million in primary-market share creations against $309.1 million in redemptions during the […] The post XRP investors poured $320M into ETFs while the funds sat on a $746M paper loss appeared first on CryptoSlate.

XRP ETF investors have poured 320M USD into funds despite the portfolios sitting 746M USD below their accounting cost. Five major US spot XRP products held XRP worth 1.7B USD at cost but only 947M USD at fair value by June 30. Despite the 44% gap, inflows continued with Bitwise, Canary and Franklin recording 484M USD net inflow. https://cryptoslate.com/xrp-investors-poured-320m-into-etfs-while-the-funds-sat-on-a-746m-paper-loss/ #Web3 #Blockchain #InstitutionalAdoption

YD Bio (Nasdaq: YDES) reported unaudited results for the six months ended June 30, 2026, with net revenue rising 315% to $0.85 million and gross profit up to $0.27 million. Revenue growth was driven mainly by higher sales of drugs and medical products, including a single Fetroja order of $327,060 that represented 39% of net revenue. Operating expenses increased 73% to $3.5 million, widening the operating loss to $3.23 million.A $9.85 million non‑cash gain from the change in fair value of warrant liabilities turned prior‑year net loss into net income of $6.7 million. Cash fell to $2.66 million, while warrant liabilities dropped to $4.52 million and shareholders’ equity moved from a deficit to $4.47 million. The company also advanced exosome and diagnostics platforms, expanded telehealth and lab coverage, and signed strategic agreements including a planned acquisition of SSMC and a U.S. agency role for YC Biotech.

SCHMID Group (NASDAQ: SHMD) reported H1 2026 revenues of €46.0 million (vs. €16.9 million H1 2025), with gross profit of €9.8 million (21.2% margin) and an operating loss of €8.0 million. Adjusted EBITDA improved to €-0.6 million from €-11.6 million, while reported net loss widened to €47.8 million due mainly to non‑cash effects from a liability-to-equity conversion and warrant fair-value movements.Order intake reached €96.6 million year‑to‑date as of August 21, 2026, with backlog at €95.0 million. SCHMID reduced financial debt by about €30 million since year‑end 2025 and converted €30.75 million of shareholder debt into equity. Following a new $20 million 2029 convertible note, cash was approximately €14.3 million on July 31, 2026, with about $21 million still available under a standby equity purchase agreement. The company reaffirmed 2026 revenue guidance of >€100 million but cut its Adjusted EBITDA margin outlook to 6–9% from >12%, and maintained order intake guidance of €125–150 million, expecting to land in the upper half.